Human MEKK3 (MAP3K3) activation kit by CRISPRa

CAT#: GA102872

MAP3K3 CRISPRa kit - CRISPR gene activation of human mitogen-activated protein kinase kinase kinase 3



  See Other Versions

CNY 12255.00


货期*
4周

规格
    • 1 kit

Product images

推荐一起购买 (2)
MEKK3 Rabbit polyclonal Antibody
    • 100 ul

CNY 1999.00
CNY 3280.00


MAP3K3 (Myc-DDK-tagged)-Human mitogen-activated protein kinase kinase kinase 3 (MAP3K3), transcript variant 2
    • 10 ug

CNY 4664.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol MAP3K3
Locus ID 4215
Kit Components

GA102872G1, MEKK3 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA102872G2, MEKK3 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA102872G3, MEKK3 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Reference Data
RefSeq NM_001330431, NM_002401, NM_203351, NM_001363768
Synonyms MAPKKK3; MEKK3
Summary This gene product is a 626-amino acid polypeptide that is 96.5% identical to mouse Mekk3. Its catalytic domain is closely related to those of several other kinases, including mouse Mekk2, tobacco NPK, and yeast Ste11. Northern blot analysis revealed a 4.6-kb transcript that appears to be ubiquitously expressed. This protein directly regulates the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by activating SEK and MEK1/2 respectively; it does not regulate the p38 pathway. In cotransfection assays, it enhanced transcription from a nuclear factor kappa-B (NFKB)-dependent reporter gene, consistent with a role in the SAPK pathway. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...